| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In order to find biomarker candidates that can discriminate subjects with mild cognitive impairment (MCI) among normal elderly, we have adopted a longitudinal follow-up study of clinical and lavoratory information and plasma sampling. Basically, comparative study of plasma samples derived from the same subject but different clinical and laboratory conditions was carried out. Within four years of clinical follow-up, we have identified six cases which developped from normal cognitive condition to MCI.
Using mass-spectrometrical analyses, one peptide candidate was found in plasma samples derived from MCI stage but not from normal stage of the all six cases. The candidate peptide which is uniquely expressed in MCI plasma have been identified as an endoproteinase cleavage pruduct of a compliment protein expressed in plasma. A novel assay system, employing a monoclonal antibody which recognizes three-dimentional structure of the C-terminalcleavage site is now under progress.
|
